tachyphylaxis


Also found in: Medical, Encyclopedia, Wikipedia.

tach·y·phy·lax·is

 (tăk′ə-fĭ-lăk′sĭs)
n. pl. tach·y·phy·lax·es (-fĭ-lăk′sēz)
1. Rapid desensitization to a toxic substance produced by inoculation with a series of small doses.
2. A rapidly decreasing response to a drug following administration of the initial doses.

tachyphylaxis

(ˌtækɪfɪˈlæksɪs)
n
(Medicine) very rapid development of tolerance or immunity to the effects of a drug
[New Latin, from tachy- + phylaxis on the model of prophylaxis. See prophylactic]
Mentioned in ?
References in periodicals archive ?
Aproclonidine, an alpha-2-adrenergic agonist, produces a lid elevation by sympathetic stimulation of the Muller muscle, but its therapeutic use is limited due to tachyphylaxis (7-12).
It needs to be considered that this supra-physiologic dosing of testosterone may in fact cause tachyphylaxis, which may lead to adverse events.
Subsequent doses are increased due to offset of the development of tachyphylaxis, which is probably due to depletion of norepinephrine stores.
There seems to be no significant tachyphylaxis over time with repeated injections.
However, prolonged treatment with octreotide may result in tachyphylaxis, which makes the treatment with agents such as interferon-[alpha] imperative.
"Having a drop that reduces redness without the side effects of rebound hyperemia or tachyphylaxis, which may lead to overuse and potential corneal toxicity, is a very exciting option that I look forward to recommending to my patients," stated Dr.
However, recently, there have been concerns regarding its use because of complications such as supraventricular tachycardia, tachyphylaxis, and the probability of fetal acidosis.
Some studies, including the TALC study comparing tiotropium versus salmeterol, have shown that patients can develop tolerance to LABAs and impaired SABA response [21, 62-64], and thus, tachyphylaxis to LABAs could preferentially favour LAMAs as an ICS add-on therapy.
GLP-1 effect on gastric emptying after a long-term, continuous use was proven recently to fade by a phenomenon of tachyphylaxis. On the contrary, insulinotropic and glucagonostatic actions of GLP-1 are not modified even after a long-term use.
In addition to all these possible explanations, patients treated with repetitive ranibizumab/ bevacizumab injections may demonstrate tachyphylaxis or a diminished therapeutic response to these agents over time as suggested in a great number of studies [24, 25].
While these results offer promise for the use of neuroprotective strategies in glaucoma, overexpression of BDNF can cause tachyphylaxis of the survival response through downregulation of TrkB and its subsequent degradation [73].